Patent ductus arteriosus

Summary

Patent ductus arteriosus (MONDO:0011827) is a disease with 7 cohort genes and 98 clinical trials. Top therapeutic interventions include ibuprofen, indomethacin, and acetaminophen.

At a glance

• Cohort genes: 7
• ClinVar variants: 12
• Clinical trials: 98

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	patent ductus arteriosus
Mondo ID	MONDO:0011827
MeSH	D004374
OMIM	607411
Orphanet	466729, 706
DOID	DOID:13832
ICD-10-CM	Q25.0
ICD-11	1262462321
NCIT	C84492
SNOMED CT	83330001
UMLS	C0013274
MedGen	4415
GARD	0024824
Is cancer (heuristic)	no

Also known as: patency of the ductus arteriosus · patent ductus arteriosus · patent ductus arteriosus familial (type) · patent ductus botalli · PDA · persistent patency of the arterial duct

Data availability: 12 ClinVar variants · 1 cell line.

Disease family

An umbrella term covering 4 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › patent ductus arteriosus

Related subtypes (59): arterial disorder, ischemic colitis, thrombotic disease, capillary disorder, angiodysplasia, hepatic vascular disorder, vascular hemostatic disease, vein disorder, ischemic disease, peripheral vascular disease, venous thromboembolism, ocular vascular disorder, cholesterol embolism, thoracic outlet syndrome, idiopathic spontaneous coronary artery dissection, cerebral arteriopathy with subcortical infarcts and leukoencephalopathy, angioosteohypertrophic syndrome, Bannayan-Riley-Ruvalcaba syndrome, arterial tortuosity syndrome, hereditary arterial and articular multiple calcification syndrome, pulmonary venoocclusive disease, multiple cutaneous and mucosal venous malformations, arterial dissection-lentiginosis syndrome, multisystemic smooth muscle dysfunction syndrome, STING-associated vasculopathy with onset in infancy, capillary malformation, Ehlers-Danlos syndrome, vascular-like type, calciphylaxis, neonatal Marfan syndrome, Ehlers-Danlos syndrome, vascular type, lethal arteriopathy syndrome due to fibulin-4 deficiency, congenital portosystemic shunt, arterial calcification of infancy, vasculitis, Loeys-Dietz syndrome, skin vascular disease, lymphatic malformation, familial thoracic aortic aneurysm and aortic dissection, congenital anomaly of superior vena cava, congenital anomaly of the inferior vena cava, congenital anomaly of hepatic vein, congenital renal artery stenosis, internal carotid agenesis, coronary sinus stenosis, coronary sinus atresia, vascular occlusion disorder, vascular insufficiency disorder, blood vessel neoplasm, vascular ectasia, vascular disorder of penis, fibrocartilaginous embolism, vascular malformation, lymphatic vessel neoplasm, neurovascular disorder, superior vena cava syndrome, coronary microvascular disorder, segmental arterial mediolysis, bleeding disorder, vascular-type, arterial tortuosity-bone fragility syndrome

Subtypes (4): Char syndrome, patent ductus arteriosus 2, patent ductus arteriosus 3, PDA1

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

12 retrieved; paginated sample, class counts are floors:

6 pathogenic, 3 pathogenic/likely pathogenic, 2 likely pathogenic, 1 uncertain significance

ClinVar	Variant (HGVS)	Gene	Classification	Review
267851	46;XX;ins(5;6)(p13;p24p25)dn		Pathogenic	criteria provided, single submitter
267941	46;XY;inv(6)(p22q13)dn		Pathogenic	criteria provided, single submitter
268044	46;XX;ins(2;9)(q24.3;p22.1p24.3)dn		Pathogenic	criteria provided, single submitter
31946	NM_020297.4(ABCC9):c.3460C>T (p.Arg1154Trp)	ABCC9	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1341468	NM_001110556.2(FLNA):c.7671del (p.Ser2558fs)	FLNA	Pathogenic	criteria provided, single submitter
93752	NM_001110556.2(FLNA):c.2761C>T (p.Arg921Ter)	FLNA	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
400	NM_019892.6(INPP5E):c.1132C>T (p.Arg378Cys)	INPP5E	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1804031	NM_002804.5(PSMC3):c.910C>T (p.Arg304Trp)	PSMC3	Pathogenic	criteria provided, single submitter
13329	NM_002834.5(PTPN11):c.184T>G (p.Tyr62Asp)	PTPN11	Pathogenic	reviewed by expert panel
267968	46;XX;inv(7)(q21.2q34)		Likely pathogenic	criteria provided, single submitter
268037	46;XY;t(2;14)(p22;q24.3)dn		Likely pathogenic	criteria provided, single submitter
2570674	NM_001358.3(DHX15):c.1327A>G (p.Lys443Glu)	DHX15	Uncertain significance	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 24 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
PMPCA	Orphanet:1170	Autosomal recessive cerebelloparenchymal disorder type 3
INPP5E	Orphanet:1454	Joubert syndrome with hepatic defect
INPP5E	Orphanet:220493	Joubert syndrome with ocular defect
INPP5E	Orphanet:475	Isolated Joubert syndrome
INPP5E	Orphanet:75858	MORM syndrome
FLNA	Orphanet:1826	Frontometaphyseal dysplasia
FLNA	Orphanet:2301	Congenital short bowel syndrome
FLNA	Orphanet:2484	Melnick-Needles syndrome
FLNA	Orphanet:482606	X-linked keloid scarring-reduced joint mobility-increased optic cup-to-disc ratio syndrome
FLNA	Orphanet:555877	FLNA-related X-linked myxomatous valvular dysplasia
FLNA	Orphanet:75497	X-linked Ehlers-Danlos syndrome
FLNA	Orphanet:88630	Terminal osseous dysplasia-pigmentary defects syndrome
FLNA	Orphanet:90650	Otopalatodigital syndrome type 1
FLNA	Orphanet:90652	Otopalatodigital syndrome type 2
FLNA	Orphanet:98892	Periventricular nodular heterotopia
FLNA	Orphanet:99811	Neuronal intestinal pseudoobstruction
ABCC9	Orphanet:130	Brugada syndrome
ABCC9	Orphanet:1517	Cantú syndrome
ABCC9	Orphanet:154	Familial isolated dilated cardiomyopathy
ABCC9	Orphanet:334	Hereditary atrial fibrillation
PTPN11	Orphanet:2499	Metachondromatosis
PTPN11	Orphanet:500	Noonan syndrome with multiple lentigines
PTPN11	Orphanet:648	Noonan syndrome
PTPN11	Orphanet:86834	Juvenile myelomonocytic leukemia

Cohort genes → proteins

7 cohort genes, 7 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	7

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
PMPCA	HGNC:18667	ENSG00000165688	Q10713	Mitochondrial-processing peptidase subunit alpha	clinvar
INPP5E	HGNC:21474	ENSG00000148384	Q9NRR6	Phosphatidylinositol polyphosphate 5-phosphatase type IV	clinvar
DHX15	HGNC:2738	ENSG00000109606	O43143	ATP-dependent RNA helicase DHX15	clinvar
FLNA	HGNC:3754	ENSG00000196924	P21333	Filamin-A	clinvar
ABCC9	HGNC:60	ENSG00000069431	O60706	ATP-binding cassette sub-family C member 9	clinvar
PSMC3	HGNC:9549	ENSG00000165916	P17980	26S proteasome regulatory subunit 6A	clinvar
PTPN11	HGNC:9644	ENSG00000179295	Q06124	Tyrosine-protein phosphatase non-receptor type 11	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
PMPCA	Mitochondrial-processing peptidase subunit alpha	Substrate recognition and binding subunit of the essential mitochondrial processing protease (MPP), which cleaves the mitochondrial sequence off newly imported precursors proteins.
INPP5E	Phosphatidylinositol polyphosphate 5-phosphatase type IV	Phosphatidylinositol (PtdIns) phosphatase that specifically hydrolyzes the 5-phosphate of phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3), phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) and phosphatidylinositol 3,5-bispho…
DHX15	ATP-dependent RNA helicase DHX15	RNA helicase involved in mRNA processing and antiviral innate immunity.
FLNA	Filamin-A	Promotes orthogonal branching of actin filaments and links actin filaments to membrane glycoproteins.
ABCC9	ATP-binding cassette sub-family C member 9	Subunit of ATP-sensitive potassium channels (KATP).
PSMC3	26S proteasome regulatory subunit 6A	Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins.
PTPN11	Tyrosine-protein phosphatase non-receptor type 11	Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus.

Protein-family classification

Druggable: 5 · Difficult: 0 · Unknown: 2 · Druggable fraction: 0.71

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Phosphatase	1	12.0×	0.260
Transporter	1	11.1×	0.260
Protease	1	5.2×	0.325
Antibody/Immunoglobulin	1	4.2×	0.325
Enzyme (other)	1	1.7×	0.548
Other/Unknown	2	0.5×	0.968

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
PMPCA	Protease	yes	3.4.24.64	Pept_M16_Zn_BS, Peptidase_M16_C, Metalloenz_LuxS/M16
INPP5E	Enzyme (other)	yes	3.1.3.36	IPPc, Endo/exonu/phosph_ase_sf, INPP5E
DHX15	Other/Unknown	no		Helicase_C-like, DNA/RNA_helicase_DEAH_CS, Helicase-assoc_dom
FLNA	Antibody/Immunoglobulin	yes		Filamin/ABP280_rpt, Actinin_actin-bd_CS, CH_dom
ABCC9	Transporter	yes		ABCC8/9, ABCC9, ABC_transporter-like_ATP-bd
PSMC3	Other/Unknown	no		AAA+_ATPase, ATPase_AAA_core, ATPase_AAA_CS
PTPN11	Phosphatase	yes	3.1.3.48	PTP_cat, Tyr_Pase_dom, SH2

Expression context

Cohort genes with no expression data: 0.

6 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	7
unknown	0

Top tissues across cohort

Tissue	Cohort genes
apex of heart	2
gastrocnemius	2
muscle of leg	2
adrenal tissue	1
right lobe of liver	1
oocyte	1
right uterine tube	1
secondary oocyte	1
cartilage tissue	1
germinal epithelium of ovary	1
tibia	1
popliteal artery	1
right coronary artery	1
tibial artery	1
hindlimb stylopod muscle	1
dorsal motor nucleus of vagus nerve	1
globus pallidus	1
medial globus pallidus	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
PMPCA	276	ubiquitous	marker	right lobe of liver, adrenal tissue, apex of heart
INPP5E	279	ubiquitous	yes	right uterine tube, secondary oocyte, oocyte
DHX15	295	ubiquitous	marker	cartilage tissue, tibia, germinal epithelium of ovary
FLNA	285	ubiquitous	marker	right coronary artery, popliteal artery, tibial artery
ABCC9	195	broad	marker	gastrocnemius, muscle of leg, hindlimb stylopod muscle
PSMC3	289	ubiquitous	marker	apex of heart, gastrocnemius, muscle of leg
PTPN11	295	ubiquitous	marker	medial globus pallidus, dorsal motor nucleus of vagus nerve, globus pallidus

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
PTPN11	6,009
DHX15	5,376
FLNA	5,321
PSMC3	4,843
PMPCA	3,679
ABCC9	1,728
INPP5E	1,309

Structural data

PDB: 5 · AlphaFold-only: 2 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
PSMC3	P17980	130
PTPN11	Q06124	115
FLNA	P21333	26
DHX15	O43143	9
INPP5E	Q9NRR6	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
PMPCA	Q10713	88.46
ABCC9	O60706	81.72

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 156. Enrichment computed across 7 evidence-associated genes (7 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 7 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Defective ABCC9 causes CMD10, ATFB12 and Cantu syndrome	1	815.7×	0.051	ABCC9
ARL13B-mediated ciliary trafficking of INPP5E	1	543.8×	0.051	INPP5E
ATP sensitive Potassium channels	1	407.9×	0.051	ABCC9
MET activates PTPN11	1	326.3×	0.051	PTPN11
Co-inhibition by BTLA	1	326.3×	0.051	PTPN11
STAT5 Activation	1	233.1×	0.051	PTPN11
Netrin mediated repulsion signals	1	181.3×	0.051	PTPN11
OAS antiviral response	1	181.3×	0.051	FLNA
MAPK1 (ERK2) activation	1	163.1×	0.051	PTPN11
STAT5 activation downstream of FLT3 ITD mutants	1	163.1×	0.051	PTPN11
MAPK3 (ERK1) activation	1	148.3×	0.051	PTPN11
Signaling by Leptin	1	148.3×	0.051	PTPN11
Interleukin-6 signaling	1	135.9×	0.051	PTPN11
GP1b-IX-V activation signalling	1	135.9×	0.051	FLNA
Activated NTRK2 signals through FRS2 and FRS3	1	135.9×	0.051	PTPN11
PECAM1 interactions	1	125.5×	0.051	PTPN11
Regulation of IFNG signaling	1	116.5×	0.051	PTPN11
Prolactin receptor signaling	1	108.8×	0.051	PTPN11
Signaling by FLT3 ITD and TKD mutants	1	108.8×	0.051	PTPN11
Spry regulation of FGF signaling	1	102.0×	0.051	PTPN11
Inwardly rectifying K+ channels	1	102.0×	0.051	ABCC9
Signal regulatory protein family interactions	1	96.0×	0.051	PTPN11
Platelet sensitization by LDL	1	96.0×	0.051	PTPN11
Cell-extracellular matrix interactions	1	96.0×	0.051	FLNA
Regulation of RUNX1 Expression and Activity	1	96.0×	0.051	PTPN11
Synthesis of PIPs at the Golgi membrane	1	90.6×	0.051	INPP5E
GAB1 signalosome	1	90.6×	0.051	PTPN11
PI-3K cascade:FGFR3	1	90.6×	0.051	PTPN11
Processing of SMDT1	1	90.6×	0.051	PMPCA
Tie2 Signaling	1	85.9×	0.051	PTPN11

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 7 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
megakaryocyte development	2	200.6×	0.006	FLNA, PTPN11
host-mediated perturbation of viral transcription	1	2407.4×	0.009	PSMC3
negative regulation of cortisol secretion	1	2407.4×	0.009	PTPN11
negative regulation of growth hormone secretion	1	2407.4×	0.009	PTPN11
regulation of membrane repolarization during atrial cardiac muscle cell action potential	1	2407.4×	0.009	FLNA
regulation of membrane repolarization during cardiac muscle cell action potential	1	2407.4×	0.009	FLNA
vasodilation	2	104.7×	0.009	ABCC9, PTPN11
microvillus organization	1	1203.7×	0.013	PTPN11
intestinal epithelial cell migration	1	1203.7×	0.013	PTPN11
response to hydrogen sulfide	1	1203.7×	0.013	ABCC9
cerebellar cortex formation	1	802.5×	0.015	PTPN11
tubulin deacetylation	1	802.5×	0.015	FLNA
negative regulation of protein localization to cilium	1	802.5×	0.015	INPP5E
formation of radial glial scaffolds	1	601.9×	0.015	FLNA
regulation of type I interferon-mediated signaling pathway	1	601.9×	0.015	PTPN11
oxygen metabolic process	1	601.9×	0.015	ABCC9
response to inositol	1	601.9×	0.015	INPP5E
adenylate cyclase-inhibiting dopamine receptor signaling pathway	1	481.5×	0.016	FLNA
ERBB signaling pathway	1	481.5×	0.016	PTPN11
establishment of Sertoli cell barrier	1	481.5×	0.016	FLNA
cellular response to chemical stress	1	401.2×	0.017	ABCC9
protein localization to bicellular tight junction	1	401.2×	0.017	FLNA
negative regulation of transcription by RNA polymerase I	1	343.9×	0.018	FLNA
negative regulation of neutrophil activation	1	343.9×	0.018	PTPN11
obsolete protein processing involved in protein targeting to mitochondrion	1	300.9×	0.018	PMPCA
blood coagulation, intrinsic pathway	1	300.9×	0.018	FLNA
reactive oxygen species biosynthetic process	1	267.5×	0.018	ABCC9
positive regulation of hormone secretion	1	240.7×	0.018	PTPN11
genitalia development	1	240.7×	0.018	PTPN11
cardiac conduction	1	240.7×	0.018	ABCC9

Therapeutics

Drugs indicated for this disease

3 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Alprostadil	Approved (phase 4)
Ibuprofen	Approved (phase 4)
Indomethacin	Approved (phase 4)
Acetaminophen	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Pentoxifylline.

Drug target analysis

Approved (phase 4): 3 · Phase ≥3: 3 · Phased (≥1): 5 · Undrugged: 2

Druggability breadth: 6 of 7 evidence-associated genes (86%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
ABCC9	PINACIDIL ANHYDROUS
PSMC3	BORTEZOMIB
PTPN11	ESTRAMUSTINE PHOSPHATE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
PTPN11	8	4
ABCC9	5	4
PSMC3	2	4
DHX15	1	2
FLNA	1	2
PMPCA	0	0
INPP5E	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
PINACIDIL ANHYDROUS	4	ABCC9
GLYBURIDE	4	ABCC9
PROPAFENONE	4	ABCC9
BORTEZOMIB	4	PSMC3
CARFILZOMIB	4	PSMC3
ESTRAMUSTINE PHOSPHATE	4	PTPN11
MOLIBRESIB	2	DHX15, FLNA
CROMAKALIM	2	ABCC9
CLAMIKALANT	2	ABCC9
ENOXOLONE	2	PTPN11
CEFSULODIN	2	PTPN11
BATOPROTAFIB	2	PTPN11
VOCIPROTAFIB	2	PTPN11
JAB-3068	1	PTPN11
PF-07284892	1	PTPN11
BBP-398	1	PTPN11

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 3.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
PTPN11	588	Binding:585, Functional:2, ADMET:1
ABCC9	61	Functional:46, Binding:15
PSMC3	27	Binding:27
DHX15	10	Binding:10
FLNA	7	Binding:7
PMPCA	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
PMPCA	3.4.24.64	mitochondrial processing peptidase
INPP5E	3.1.3.36	phosphoinositide 5-phosphatase
PTPN11	3.1.3.48	protein-tyrosine-phosphatase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
PTPN11	588

Pharmacogenomics

Cohort genes with a PharmGKB record: 7; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

16 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
PINACIDIL ANHYDROUS	4	ABCC9
GLYBURIDE	4	ABCC9
PROPAFENONE	4	ABCC9
BORTEZOMIB	4	PSMC3
CARFILZOMIB	4	PSMC3
ESTRAMUSTINE PHOSPHATE	4	PTPN11
MOLIBRESIB	2	DHX15, FLNA
CROMAKALIM	2	ABCC9
CLAMIKALANT	2	ABCC9
ENOXOLONE	2	PTPN11
CEFSULODIN	2	PTPN11
BATOPROTAFIB	2	PTPN11
VOCIPROTAFIB	2	PTPN11
JAB-3068	1	PTPN11
PF-07284892	1	PTPN11
BBP-398	1	PTPN11

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	3	ABCC9, PSMC3, PTPN11
B	Phased (≥1) drug, not yet approved	2	DHX15, FLNA
C	Druggable family + PDB, no drug	1	INPP5E
D	Druggable family + AlphaFold only, no drug	1	PMPCA
E	Difficult family or no structure, no drug	0

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
PMPCA	1	—
INPP5E	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 98.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	63
PHASE2	10
PHASE3	8
PHASE4	7
PHASE2/PHASE3	5
PHASE1/PHASE2	2
PHASE1	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00217191	PHASE4	COMPLETED	Ibuprofen and Renal Function in Premature Infants
NCT00642330	PHASE4	COMPLETED	Comparative Study of Efficacy and Safety of Oral Ibuprofen and Intravenous Ibuprofen in Closure of Patent Ductus Arteriosus in Very Low Birth Weight Infants
NCT00767039	PHASE4	TERMINATED	Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants
NCT00961753	PHASE4	TERMINATED	Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates
NCT01536158	PHASE4	COMPLETED	Oral Paracetamol Versus Oral Ibuprofen in Management of Patent Ductus Arteriosus in Preterm Infants: A Randomised Controlled Trial
NCT01544972	PHASE4	UNKNOWN	Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants
NCT03265782	PHASE4	UNKNOWN	Paracetamol Versus Ibuprofen for PDA Closure
NCT03456336	PHASE3	ACTIVE_NOT_RECRUITING	Management of the PDA Trial
NCT00440804	PHASE3	COMPLETED	Safety and Efficacy Study of Ibuprofen l-Lysine Solution in Premature Infants for Treatment of PDA
NCT00485160	PHASE3	COMPLETED	Ibuprofen vs. Continuous Indomethacin in the Treatment of PDA
NCT00750581	PHASE2/PHASE3	TERMINATED	An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants
NCT01593163	PHASE3	COMPLETED	Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus
NCT01630278	PHASE3	COMPLETED	Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI)
NCT01755728	PHASE3	COMPLETED	Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants
NCT02620761	PHASE2/PHASE3	TERMINATED	Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants
NCT03022253	PHASE3	COMPLETED	Platelet Transfusion for Treatment of Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates
NCT03537144	PHASE3	TERMINATED	Acetaminophen vs Indomethacin in Treating hsPDA
NCT04459117	PHASE2/PHASE3	COMPLETED	Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen
NCT04986839	PHASE2/PHASE3	UNKNOWN	PAIR (Paracetamol and Ibuprofen Research) Pilot Trial
NCT07067177	PHASE2/PHASE3	COMPLETED	Prophylactic IV Paracetamol in Extremely Premature Infants
NCT07143201	PHASE2	RECRUITING	Precision Dosing of Oral Ibuprofen for PDA, A Pilot RCT
NCT00187447	PHASE2	COMPLETED	Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at <28 Weeks Gestation With a Persistent Patent Ductus Arteriosus
NCT00616382	PHASE2	UNKNOWN	Treating the Resistant Patent Ductus Arteriosus (PDA)
NCT01070745	PHASE2	WITHDRAWN	Second Course of Therapy for Resistant Patent Ductus Arteriosus (PDA)
NCT01149564	PHASE1/PHASE2	UNKNOWN	Comparison of Oral and Intravenous Ibuprofen for PDA Treatment in Premature Infants
NCT01291654	PHASE2	UNKNOWN	Paracetamol and Patent Ductus Arteriosus (PDA)
NCT01958320	PHASE2	COMPLETED	Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus
NCT02819414	PHASE2	UNKNOWN	Paracetamol Treatment of the Borderline Significant PDA
NCT03701074	PHASE2	TERMINATED	Randomized Controlled Trial to Evaluate the Safety and Efficacy of Acetaminophen in Preterm Infants Used in Combination With Ibuprofen for Closure of the Ductus Arteriosus
NCT04026464	PHASE2	WITHDRAWN	Addition of Acetaminophen in Standard PDA Management
NCT06152796	PHASE2	UNKNOWN	Comparision Between Paracetamol and Ibuprofen in Closure of Patent Ductus Arteriosus
NCT06256211	PHASE1/PHASE2	UNKNOWN	Assessment of Therapeutic Effect of Rectal Vs. Intravenous Paracetamol in The Treatment of Patent Ductus Arteriosus (PDA) in Neonates
NCT03103022	PHASE1	COMPLETED	Combination of Acetaminophen and Ibuprofen in the Management of Patent Ductus Arteriosus
NCT03648437	PHASE1	TERMINATED	Paracetamol And Ibuprofen/Indomethacin in Closing Patent Ductus Arteriosus
NCT06298344	EARLY_PHASE1	COMPLETED	The Role of Thiamine After Transcatheter Closure in Children With Left-to-Right Shunt Congenital Heart Disease
NCT03782610	Not specified	ACTIVE_NOT_RECRUITING	Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes
NCT04371081	Not specified	ACTIVE_NOT_RECRUITING	Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance
NCT05264753	Not specified	RECRUITING	Post Marketing Clinical Follow Up Study to Evaluate Efficacy and Safety of the Occlutech PDA Occluder in Patients With Patent Ductus Arteriosus Defects
NCT06045130	Not specified	NOT_YET_RECRUITING	PUFAs in Preterm Infants
NCT06587282	Not specified	ACTIVE_NOT_RECRUITING	PREEMIE: Study for Treatment of PDA in Premature Infants

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IBUPROFEN	4	31
INDOMETHACIN	4	6
ACETAMINOPHEN	4	2
THIAMINE ION	4	2
BERACTANT	4	1
DEXTROSE	4	1
FENOLDOPAM	4	1
PENTOXIFYLLINE	4	1
PORACTANT ALFA	4	1
CHEMBL5592090	0	3